Global ELISpot and FluoroSpot Assay Market Size, Trends & Analysis - Forecasts to 2026 By Product (Assay Kits, Ancillary Products, Analyzers), By End-User (Hospitals & Clinical Laboratories, Biopharmaceutical Companies, Research Institutes), By Application (Diagnostic Applications, Research Applications), By Region (North America, Asia Pacific, Europe, Latin America, Middle East & Africa); End-User Landscape, Company Market Share Analysis, and Competitor Analysis
The most frequently used immune assays, ELISpot and FluoroSpot, use fluorophores labeled detection reagents to evaluate the immune systems activity at the single-cell stage. The cells are grown on antigen-coated surfaces, which prevent the release of particular target molecules. The technique employs antibody-coated microplates on which sample cells are cultured. Antibodies bind to unique molecules released by activated cells, preventing them from spreading. The FluoroSpot assay allows for the measurement of multiple analytes secreted by a single cell at the same time. This highly sensitive cellular assay is accurate, simple to use, and can be used for large-scale screening and single tests.
The cells are then moved to the microplate and incubated at 37 °C for a specific amount of time. Following the completion of the incubation cycle, an antigen-antibody conjugate is produced, which is then processed to extract the unbound analyte. An individual analyte secreting cell is represented by a blue-black precipitate.
The rising number of clinical trials along with the growing occurrence of cancer globally has positively influenced the elispot and fluorospot assay market growth. Furthermore, technological developments in ELISpot and FluoroSpot assay kits and analyzers, as well as growing healthcare spending in developing nations, are expected to drive market growth throughout the forecast period.
The market is expected to expand as people become more conscious of numerous infections diagnoses.Furthermore, government support for R&D has resulted in the production of creative products in the sector. As per the Globocan 2020 study, there were 19,292,789 new cancer cases diagnosed worldwide, with 9,958,133 cancer-related deaths.
The surge in geriatric population and disposable income is primarily responsible for the growing penetration of the ELISpot and FluoroSpot assay markets. The market is expected to expand due to growing vaccine production and new manufacturing techniques for elispot and fluorospot assay analyzers.
During the forecast era, the assay kits segment expected to hold the largest share. The rising occurrence of chronic illness, along with thetechnicalinnovation of assay kits and analyzers, are propelling themarket growth. Moreover, one of the major factors driving the segments growth during the projected timeframe is the rising use of these products for vaccine production in clinical studies.According to the World Health Organisation, the major chronic diseases currently account for approximately 60% of all deaths and 43% of the global disease burden.
Elispot and fluorospot assay market end-user segment is dominated by the hospitals and clinical laboratories to hold the largest market share over the forecast timeframe.This is due to the highly targeted population of hospital-preferred patients especially in developing nations, the increasing number of hospital procedures, the increasing emphasis on the effective and early detection of diseases in hospitals, and the improvement in the efficiency of diagnostic applications. Furthermore, the growing number of cancer-related research studies conducted in hospitals is expected to fuel hospital market development.
The biopharmaceutical companies will witness the highest growth over the forecast era.The growing emphasis on research and related investment is increasing to meet the huge demand for biopharmaceuticals. Biopharmaceutical companies potential to treat previously untreatable diseases has resulted in the introduction of novel drugs to the market. The market under analysis is expected to expand during the forecast period as a result of the factors mentioned.
Over the projected timeframe, the diagnostic application segment is projected to hold the largest revenue share of the market.This is due to the increasing incidence of infectious diseases, chronic illness globally, and the rising use of ELISpot kits for diagnosing diseases.
The research application segment is expected to expand at a rapid rate due to increasing research activities on novel cancer diagnosis assay production and rising cancer prevalence around the world.
The ELISpot and FluoroSpot Assay market in North America accounted for the majority revenue share of the market.The increasing incidence of infectious illness in the United States and Canada, the increasing number of elderly patients, and the presence of well-established market players in the region are all expected to fuel market growth. Also, better advancement in healthcare infrastructure led to the demand in this region.
The Asia Pacific region market is expected to grow significantly throughout 2021 and 2026.This is attributed to a rise in the number of assay kit producers, mergers and acquisitions, and rising investment in healthcare facilities, all of which would attract new entrants into the industry.
In terms of market share, Europe was the second-largest market for ELISpot and FluoroSpot assays in 2019. Increased product approvals, growing awareness, multinational manufacturers implementing expansion strategies in multiple regions to broaden global footprint, strategic acquisition of local and medium-scale manufacturers to improve product portfolio, and growing R&D operation are anticipated to fuel the market growth in the European region.Some of the key factors driving the growth of this regional market are the emergence of emerging countries such as South Korea, China, and India, the high population pool, and the growing number of collaborations for life science research studies.
Oxford Immunotec, Mabtech AB, Abcam, AutoimmunDiagnostika GmbH, Lophius Biosciences GmbH, Cellular Technology Limited (CTL), Becton, Dickinson and Company, Bio-Techne, Biotech Investissement Group, and U-Cytech Biosciences, are some of the key identified industry players in the market.
Please note: This is not an exhaustive list of companies profiled in the report.
In February 2020, Mabtech introduced its new products monoclonal antibodies (mAbs), ELISpot, and ELSI kits for the detection of human EBI3
In May 2018, Oxford Immunotec launched its new brand AccutixTM. Oxford Immunotecs tick-borne disease offering, which involves more than 20 testing solutions for eight tick-borne diseases, is now known as Accutix. Under the Accutix brand, the company will continue to develop new assays for both current and emerging tick-borne diseases.
We value your investment and offer free customization with every report to fulfil your exact research needs.
The Global ELISpot and FluoroSpot Assay Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the ELISpot and FluoroSpot Assay Market
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?